JPWO2019204233A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019204233A5
JPWO2019204233A5 JP2020558506A JP2020558506A JPWO2019204233A5 JP WO2019204233 A5 JPWO2019204233 A5 JP WO2019204233A5 JP 2020558506 A JP2020558506 A JP 2020558506A JP 2020558506 A JP2020558506 A JP 2020558506A JP WO2019204233 A5 JPWO2019204233 A5 JP WO2019204233A5
Authority
JP
Japan
Prior art keywords
olfr
agent
expression
use according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020558506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521248A (ja
JP2021521248A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027558 external-priority patent/WO2019204233A1/en
Publication of JP2021521248A publication Critical patent/JP2021521248A/ja
Publication of JP2021521248A5 publication Critical patent/JP2021521248A5/ja
Publication of JPWO2019204233A5 publication Critical patent/JPWO2019204233A5/ja
Pending legal-status Critical Current

Links

JP2020558506A 2018-04-16 2019-04-15 嗅覚受容体活性を標的とすることによる免疫応答のモジュレート Pending JP2021521248A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658581P 2018-04-16 2018-04-16
US62/658,581 2018-04-16
PCT/US2019/027558 WO2019204233A1 (en) 2018-04-16 2019-04-15 Modulating immune response via targeting of olfactory receptor activity

Publications (3)

Publication Number Publication Date
JP2021521248A JP2021521248A (ja) 2021-08-26
JP2021521248A5 JP2021521248A5 (https=) 2022-04-25
JPWO2019204233A5 true JPWO2019204233A5 (https=) 2022-04-25

Family

ID=68240310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020558506A Pending JP2021521248A (ja) 2018-04-16 2019-04-15 嗅覚受容体活性を標的とすることによる免疫応答のモジュレート

Country Status (4)

Country Link
US (1) US20210145768A1 (https=)
EP (1) EP3781173A4 (https=)
JP (1) JP2021521248A (https=)
WO (1) WO2019204233A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3827816A1 (en) * 2019-11-28 2021-06-02 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases
WO2021257905A2 (en) * 2020-06-17 2021-12-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Olfactory receptors for use as targets for antigen binding molecules to detect and treat cancer
WO2022128050A1 (en) * 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain
JP2022187352A (ja) * 2021-06-07 2022-12-19 エステー株式会社 嗅覚受容体の阻害剤、消臭剤、消臭方法
JP2023084473A (ja) * 2021-12-07 2023-06-19 花王株式会社 フェノール化合物を原因とするにおいの抑制剤の評価及び／又は選択方法
EP4241766A1 (en) * 2022-03-07 2023-09-13 Fondazione Per L'Istituto Oncologico Di Ricerca (IOR) Use of olfactory receptor or13a1 ligands in the treatment of lymphomas
IT202200010358A1 (it) * 2022-05-18 2023-11-18 Giuliani Spa Agonista del recettore olfattivo 2a4/7 per promuovere la crescita di capelli e migliorare l’aspetto estetico / olfactory receptor 2a4/7 agonist for promoting hair growth and improving aesthetic aspect
CN115840026B (zh) * 2023-02-13 2023-05-23 汉王科技股份有限公司 嗅觉受体在识别4-甲氧基苯甲醛中的用途和检测4-甲氧基苯甲醛的方法
KR20250044488A (ko) * 2023-09-21 2025-04-01 성균관대학교산학협력단 후각수용체 Olfr164를 제어하는 패혈증 치료용 조성물
CN118178367B (zh) * 2023-12-11 2024-09-13 南方医科大学 一种治疗胶质母细胞瘤的药物及其应用
US12290550B1 (en) 2023-12-27 2025-05-06 Olfactive Ai, Inc. Compositions and methods for treating endocrine diseases and disorders
US12102611B2 (en) * 2024-03-25 2024-10-01 Olfactive Biosolutions, LLC Compositions and methods for treating hypertension by modulating endocrine activity
WO2025187455A1 (ja) * 2024-03-08 2025-09-12 株式会社 資生堂 メラノサイトに対する紫外線の影響の抑制剤
CN120960185A (zh) * 2025-09-03 2025-11-18 江西农业大学 麝香酮在制备病毒抑制剂中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
US20110196383A1 (en) 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
CA2993567C (en) 2010-07-21 2022-06-28 Sangamo Biosciences, Inc. Methods and compositions for modification of a t-cell receptor gene
KR101050436B1 (ko) * 2010-12-09 2011-07-19 연세대학교 산학협력단 대사질환과 연관된 후각수용체 유전자 및 그의 용도
JP5298258B1 (ja) * 2011-10-26 2013-09-25 パナソニック株式会社 マウス嗅覚受容体Ｏｌｆｒ１５を細胞膜に発現する方法
EP3038609B1 (en) * 2013-08-27 2021-07-28 Deutsches Krebsforschungszentrum Cytotoxic t cell response modifiers
US11123292B2 (en) 2014-01-29 2021-09-21 Catherine S. Beaudin Use of biocompatible microdroplets for the treatment of atherosclerosis, heart disease and stroke
CN103976987A (zh) 2014-06-04 2014-08-13 古天津 一种用于治疗动脉粥状硬化的组合物
CN106668050A (zh) 2017-01-22 2017-05-17 新乡医学院 治疗动脉粥样硬化的药物组合物及应用

Similar Documents

Publication Publication Date Title
JP2021521248A5 (https=)
JPWO2019204233A5 (https=)
Kim et al. HMGB1 contributes to the development of acute lung injury after hemorrhage
Germano et al. Cytokines as a key component of cancer-related inflammation
KR102701893B1 (ko) 악성종양을 치료하기 위한 조합 요법
JP2020002152A (ja) グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用
JP2010043114A (ja) 腫瘍転移および癌の治療
JP2008531502A (ja) 胃腸の炎症を処置する方法
JP2021513536A5 (https=)
JP2021512056A (ja) 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること
Mukherjee et al. TAM receptor tyrosine kinase function and the immunopathology of liver disease
JP2021519302A5 (https=)
WO2024078592A1 (zh) 靶向成纤维细胞活化蛋白的药物及其应用
Sarantis et al. Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy
JP2025526644A (ja) 高精度のがん処置のための組成物および方法
Kwantwi Interplay between tumor-derived factors and tumor-associated neutrophils: opportunities for therapeutic interventions in cancer
Ning et al. Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study
Shao et al. Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells
Aripova et al. Citrullinated and malondialdehyde-acetaldehyde-modified fibrinogen activates macrophages and promotes profibrotic responses in human lung fibroblasts
JPWO2019154986A5 (https=)
JP2024540524A (ja) 抗体－薬物コンジュゲート及びｐａｒｐ１選択的阻害薬の組み合わせ
JP7787823B2 (ja) Ｃｃｒ９阻害剤及び抗ｉｌ－２３遮断抗体を使用する炎症性腸疾患を治療するための組成物及び方法
US20210187072A1 (en) Methods and compositions for reducing risk of relapse and prolonging survival in acute myeloid leukemia
JP2023502267A (ja) ＣＣＲ９阻害剤および抗ＴＮＦ－α遮断抗体を使用してＣＣＲ９媒介性疾患を治療するための組成物および方法
Wolin Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors